UT Arlington - Science and Engineering Innovation and Research Building
Arlington, Texas, 76010, United States
NCT Number: NCT06497413
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Arlington, Texas, 76010, United States
Neurocognitive conditions and diseases including cognitive dysfunction, Alzheimer's disease and related dementias (ADRD) are among the fastest growing causes of morbidity and mortality. ADRDs impact > 5 million people in the United States alone and > 47 million people worldwide. The physiological reasons for these conditions are multifactorial but one contributing factor is impaired cerebral vascular function/health. Importantly, impaired cerebral vascular function/health results in cerebral hypoperfusion thereby contributing to neuronal damage and neurodegenerative processes ultimately contributing to the aforementioned neurocognitive impairments. Furthermore, it is critical to investigate therapeutic strategies to combat this elevated risk. One promising approach is Transcranial Photobiomodulation (tPBM) which is a novel and non-invasive strategy that utilizes low-level laser therapy to activate intracellular enzymatic pathways leading to an increase in mitochondrial activity, cerebral oxygenation, and thus neural and overall brain function. Importantly, this approach improves cognitive function in various animal models and limited human populations. Furthermore, there is limited evidence to suggest that these neurocognitive improvements are in-part related to increases in cerebral blood flow and cerebral vascular function/health. However, information regarding the mechanisms and effectiveness of tPBM are still relatively unknown - which represents a critical knowledge gap in the literature.
Therefore, the overall research objective is of this proposal is to determine the impact of tPBM on indices of neurocognitive and cerebral vascular health. The following objectives / aims will be explored:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
Time frame: Immediately before the start of the experimental or sham condition intervention. And immediately after the end of the experimental or sham condition intervention.
This will be assessed as the increase in blood flow in the middle cerebral artery during a hypercapnic stimulus
Time frame: Immediately before the start of the experimental or sham condition intervention. And immediately after the end of the experimental or sham condition intervention.
This will be assessed using the NIH Toolbox which is a battery that consists of several cognitive challenges.
The University of Texas at Arlington
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05462977
Affect, Alzheimer Disease
Greensboro, North Carolina, United States
View Trial DetailsNCT03721705
Alzheimer Disease, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04975464
Alzheimer Disease, Arterial Occlusive Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT06733714
Alzheimer Disease, Arterial Occlusive Diseases
Rio de Janeiro, Brazil
View Trial Details